Category Archives: Biotechnology Industry Organization

The next episode of the American horror story

You’ve likely heard the terrified screams induced by the cost of pricey cancer drugs, Gilead Sciences Inc.’s twin hepatitis C therapies and Vertex’s cystic fibrosis breakthroughs. And you may have been rattled by the nightmarish predictions about how a new…

Share

States move forward as SEC lags on crowdfunding rules

With a new year, old impatience is growing among small companies and investors eager to see the potential of federally sanctioned crowdfunding take off. In January, biotech hotbed Massachusetts, as well as Oregon and Maine, joined a growing list of…

Share

Old dogs and new tricks: The real-world consequences of excluding older adults from drug trials

How much time do you spend with old people? That’s a loaded question, of course. Age is a relative term, since we age every day and so does the world’s population. Even though the global median age was estimated at…

Share

Balancing innovation and access: The policy conundrum

RIO DE JANEIRO – I was in college when I first read Ayn Rand’s Atlas Shrugged. Safe within the privileged and idealistic bubble of academia, I found myself agreeing with Rand at every turn, filled with the pro-capitalist and individualist…

Share

Biopeople to Meet at BIO2013: Inside the World of Biotech’s Luminaries, Titans and Brainiacs

Partnering, networking and making new friends are all top-of-the-agenda for the biopharma industry’s largest U.S. gathering. As you’re preparing to join 16,500+ of your colleagues at the 2013 BIO International Convention in Chicago, we’d like to introduce you to a…

Share

The Times They Are A-Changin’

Kudos to the folks at Biotechnology Industry Organization (BIO) for selecting the industry’s “hot button” issues for panel discussions at the annual BIO Investor Forum (BIF) just concluded in San Francisco. In years past it has been my experience that…

Share

BIO-Buzzwords Won’t Die, So We May as Well Evolve Them

For BIO 2011, BioWorld published a list of overused BioCliches to shun, and I was pleased to observe that attendees and speakers must’ve taken notice and avoided using them at BIO 2012 this year. However, since the urge to use…

Share

Michael’s Personal BIO 2012 Wrap-Up

Day One: The wait is over! I leap off the bus and race the other lively stepping attendees to the registration corridor, exchanging pleasantries with everyone I pass. My first-day euphoria high carries me though five sessions, over three miles…

Share

A Stifled U.S. Biotech Sector: Is it Too Late to Recover?

BOSTON ‑ Amid all of the excitement that comes with the biopharma industry’s largest annual gathering in Boston this week, I’m worried about the future. The U.S. has lost too much ground ‑ due to the obvious partisan gridlock in…

Share

Find Your Lucky Number at BIO 2012

BOSTON – The 2012 BIO International Convention may have fallen a tad short of its nadir in 2007, when BIO attendance topped more than 20,000 people from 49 U.S. states, Washington D.C., Puerto Rico and more than 60 countries. But…

Share